Pancragen
Metabolic / PancreaticAlso known as: Lys-Glu-Asp-Trp, KEDW
Mechanism
A tetrapeptide bioregulator that targets pancreatic tissue. It helps normalize insulin secretion and blood glucose levels. Part of Professor Khavinson's organ-specific peptide series, where short peptides (2-4 amino acids) are matched to specific organs. Studied primarily in diabetic animal models and in Russian clinical settings.
Technical detail
Synthetic tetrapeptide (Lys-Glu-Asp-Trp) designed as a pancreatic bioregulator per Khavinson's peptide bioregulation theory. Proposed mechanism: sequence-specific interaction with gene promoter regions in pancreatic beta cells, modulating transcription of insulin-related genes. Animal studies (streptozotocin-induced diabetes models) show normalization of blood glucose, improved insulin secretion, and restoration of pancreatic islet morphology. Khavinson's hypothesis: short peptides penetrate cells and interact with DNA in a sequence-specific manner, acting as epigenetic regulators. Published in Bulletin of Experimental Biology and Medicine (Khavinson et al.).
Effects
## Pancragen — System-by-System Effects ### Pancreatic/Endocrine System (Primary Target) - **Beta cell function**: Pancragen (Lys-Glu-Asp-Trp tetrapeptide) targets pancreatic tissue, particularly insulin-producing beta cells. Designed to restore optimal gene expression and functional capacity of aging/stressed pancreatic cells. [Tier 2 — Khavinson bioregulator research] - **Insulin secretion optimization**: Supports appropriate insulin secretion patterns. May improve first-phase insulin response, which is often the earliest defect in type 2 diabetes progression. [Tier 2-3] - **Beta cell preservation**: May slow the loss of functional beta cell mass that occurs in aging and metabolic disease. Protective rather than regenerative in nature. [Tier 2-3] - **Glucose homeostasis**: Patients report improved fasting glucose and HbA1c values after sustained use. Effects are modest — this is a supportive intervention, not a diabetes drug. [Tier 3] ### Digestive System - **Exocrine pancreas**: The exocrine pancreas produces digestive enzymes. Pancragen may support enzyme production capacity, improving digestion. [Tier 3] - **Digestive efficiency**: Some patients report improved digestion and reduced bloating, possibly through enhanced pancreatic enzyme output. [Tier 3] ### Metabolic System - **Blood sugar regulation**: Through improved beta cell function, pancragen may contribute to more stable blood sugar levels throughout the day. [Tier 3] - **Insulin sensitivity (indirect)**: By optimizing insulin secretion patterns, may indirectly improve peripheral insulin sensitivity through reduced hyperinsulinemia. [Tier 3]
Practitioner Guide
## Pancragen — Practitioner Guide ### Clinical Profile Pancragen is a synthetic tetrapeptide (Lys-Glu-Asp-Trp) bioregulator targeting pancreatic tissue. Khavinson cytogens class. Used to support pancreatic function in aging and early metabolic disease. ### Typical Protocols - **Standard course**: 1-2 capsules daily for 30 days, repeat 2-3 times per year - **Metabolic support**: 2 capsules daily during metabolic optimization protocols - **Prevention**: 1 capsule daily for 30 days, 2x/year for patients with family history of diabetes or prediabetes ### Best Candidates - Patients with prediabetes (impaired fasting glucose or impaired glucose tolerance) - Aging patients (50+) with declining glucose homeostasis - Type 2 diabetics as adjunct to standard therapy (not a replacement) - Patients with family history of diabetes seeking prevention - Post-pancreatitis patients seeking pancreatic tissue support ### Combination Strategies - **Metabolic optimization**: Pancragen + berberine + chromium + dietary modification - **Bioregulator metabolic**: Pancragen (pancreas) + Svetinorm (liver) — comprehensive metabolic organ support - **Diabetes prevention**: Pancragen + exercise program + Mediterranean diet + metformin (if indicated) ### Important Limitations - Not a substitute for diabetes medications - Cannot reverse established type 2 diabetes or regenerate destroyed beta cells - Modest effects — best used preventively or as adjunct - Evidence base is limited to bioregulator research program and clinical observation - Monitor blood glucose and HbA1c to track any benefit objectively
Research Summary
## Pancragen — Research Summary ### Tier 1 - No Western RCTs available. ### Tier 2 - Khavinson bioregulator research program publications showing pancragen modulates gene expression in pancreatic cell cultures. - In vitro studies demonstrating improved insulin secretion from beta cell lines treated with KEDW peptide. - Animal studies showing improved glucose tolerance in diabetic rodent models. ### Tier 3 - Clinical observations from European practitioners report modest improvements in fasting glucose and HbA1c. - Practitioner experience supports use in prediabetic and early diabetic populations as adjunct therapy. - Best results reported when combined with lifestyle modifications. ### Key Research Gaps - No RCTs or placebo-controlled human studies - No pharmacokinetic validation of oral tetrapeptide absorption - No comparison with established diabetes prevention strategies (metformin, lifestyle intervention) - Long-term outcomes data unavailable